RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor

Bryce et al., NCT04470544, RECOVER, NCT04470544

Mar 2024

Source PDF All Studies Meta AnalysisMeta

RCT 100 patients showing no significant difference with camostat. Results are currently unclear—different mortality numbers were provided for all-cause mortality and mortality rate (2/50 vs. 3/46 for the treatment group at 28 days, with the 28 day all-cause mortality result removed in an updated submission). The main outcome measures appear to be different due to only including patients that submitted day 28 outcome data.

Important missing comments or errors? Let us know.

risk of death, 25.0% lower, RR 0.75, p = 1.00, treatment 3 of 50 (6.0%), control 4 of 50 (8.0%), NNT 50, day 56.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Bryce et al., 28 Mar 2024, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04470544 (history) (RECOVER). Contact: Nguyen.Vy@mayo.edu, ClinicalResearch@tmcaz.com, Vimoktayon.Torsak@mayo.edu, Pecenka.Stacey@mayo.edu.

This Paper Camostat All

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0